• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性乳腺癌的优化管理

Optimal Management of Primary Breast Cancer.

作者信息

Soran Atilla, Vogel Victor G.

机构信息

University of Pittsburgh Cancer Institute/Magee-Womens Hospital, Pittsburgh, Pennsylvania.

出版信息

Breast J. 1999 Mar;5(2):81-93. doi: 10.1046/j.1524-4741.1999.00130.x.

DOI:10.1046/j.1524-4741.1999.00130.x
PMID:11348265
Abstract

The diagnosis and treatment of breast cancer have changed in response to not only new technologies but also cultural and social aspects of the disease. While breast-conserving surgery and adjuvant therapy are the preferred treatments for many breast cancers, neoadjuvant therapy is often used in advanced disease. In this review we examine the treatment options that are influenced by pathologic and clinical factors. Invasive breast cancer is a potentially curable disease if it is regarded and managed by a multidisciplinary approach from the outset.

摘要

乳腺癌的诊断和治疗不仅因新技术,也因该疾病的文化和社会层面而发生了变化。虽然保乳手术和辅助治疗是许多乳腺癌的首选治疗方法,但新辅助治疗常用于晚期疾病。在本综述中,我们研究了受病理和临床因素影响的治疗选择。如果从一开始就采用多学科方法来认识和管理浸润性乳腺癌,那么它是一种潜在可治愈的疾病。

相似文献

1
Optimal Management of Primary Breast Cancer.原发性乳腺癌的优化管理
Breast J. 1999 Mar;5(2):81-93. doi: 10.1046/j.1524-4741.1999.00130.x.
2
Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.紫杉醇和表柔比星新辅助治疗浸润性乳腺癌:一项II期研究。
Clin Drug Investig. 2006;26(12):691-701. doi: 10.2165/00044011-200626120-00003.
3
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
4
Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.可手术乳腺癌患者新辅助化疗后的保乳手术
Ann Ital Chir. 2018;89:290.
5
Current and future role of neoadjuvant therapy for breast cancer.新辅助治疗在乳腺癌中的当前及未来作用
Breast. 2014 Oct;23(5):526-37. doi: 10.1016/j.breast.2014.06.004. Epub 2014 Jul 14.
6
Breast cancer: current issues in diagnosis and treatment.乳腺癌:诊断与治疗的当前问题
Aust N Z J Surg. 1997 Jan;67(1):47-58. doi: 10.1111/j.1445-2197.1997.tb01894.x.
7
Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties.乳腺癌新辅助全身治疗:挑战与不确定性
Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:144-156. doi: 10.1016/j.ejogrb.2016.12.014. Epub 2016 Dec 14.
8
Regarding: Valero V, Buzdar AU, Hortobagyi GN. "Locally Advanced Breast Cancer," The Oncologist 1996;1:8-17.关于:瓦莱罗·V、布兹达尔·A·U、霍尔托巴吉·G·N。《局部晚期乳腺癌》,《肿瘤学家》1996年;第1卷:第8 - 17页。
Oncologist. 1996;1(4):278-279.
9
Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer.新辅助化疗可提高早期可手术乳腺癌的保乳手术率。
Hong Kong Med J. 2017 Jun;23(3):251-7. doi: 10.12809/hkmj164972. Epub 2017 May 9.
10
Primary systemic therapy of breast cancer.乳腺癌的原发性全身治疗
Oncologist. 2006 Jun;11(6):574-89. doi: 10.1634/theoncologist.11-6-574.

引用本文的文献

1
Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats.聚乙二醇-阿霉素共轭纳米载体导管内给药治疗大鼠原位导管癌(DCIS)样病变的评估。
J Interdiscip Nanomed. 2018 Oct 15;3(3):146-159. doi: 10.1002/jin2.51. eCollection 2018 Sep.
2
[Suspected contrast medium concentration in dynamic MR-mammography. Post-traumatic fracture of the ribs].
Radiologe. 2002 Sep;42(9):753-5. doi: 10.1007/s00117-002-0792-4.